2
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other hematologic neoplasm
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Breast Neoplasms
625
Stomach Neoplasms
75
Neoplasm Metastasis
59
Neoplasms
39
HER2-positive Breast Cancer
33
Breast Neoplasms, Male
30
Colorectal Neoplasms
28
Brain Neoplasms
25
Carcinoma, Non-Small-Cell Lung
21
Inflammatory Breast Neoplasms
20
Esophageal Neoplasms
20
Pancreatic Neoplasms
13
Triple Negative Breast Neoplasms
12
Lung Neoplasms
11
Endometrial Neoplasms
11
Ovarian Neoplasms
10
Colonic Neoplasms
10
Urinary Bladder Neoplasms
9
Rectal Neoplasms
9
Prostatic Neoplasms
9
Cardiotoxicity
8
Adenocarcinoma
8
Salivary Gland Neoplasms
7
Gallbladder Neoplasms
7
Breast Diseases
7
Biliary Tract Neoplasms
7
Adenocarcinoma Of Esophagus
7
Uterine Cervical Neoplasms
6
Squamous Cell Carcinoma of Head and Neck
6
Sarcoma
6
Interventions
pembrolizumab
24
Nivolumab
23
aldesleukin
21
Cyclophosphamide
20
Ipilimumab
17
Interleukin-2
17
fludarabine
15
fludarabine phosphate
14
cemiplimab
12
Radiotherapy
7
Fluorouracil
7
Biopsy
7
dabrafenib
6
Surveys and Questionnaires
6
Dacarbazine
6
trametinib
5
binimetinib
5
Vemurafenib
5
Temozolomide
5
Surgical Procedures, Operative
5
Sirolimus
5
Radiation
5
Blood Specimen Collection
5
Aminolevulinic Acid
5
sonidegib
4
encorafenib
4
Photochemotherapy
4
Mohs Surgery
4
HhAntag691
4
Educational Status
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Skin Neoplasms
×
Trastuzumab
×
Clear all
NCT05786716
2025-12-02
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled